Eisai Co., Ltd. (4523.T) Stock
Eisai Co., Ltd.

Company profile
Eisai reported revenue of 789.40 billion JPY for fiscal year 2025, up 6.4% from fiscal year 2024, and net income of 46.43 billion JPY. That is a net profit margin of 5.9% for fiscal year 2025. Its largest business segment, Pharmaceutical Business - Americas, brought in 35% of segment revenue in fiscal year 2025; United States was the largest region with 35%. Our analysis of its filings shows revenue growing from 744.40 billion JPY in fiscal year 2023 to 789.40 billion JPY in fiscal year 2025, 3.0% a year on average. Eisai reports about 10,543 full-time employees.
What stands out
- It spent 171.63 billion JPY on research and development in fiscal year 2025, 21.7% of its revenue.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended March 31, 2025.
About Eisai Co., Ltd.
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Largest shareholders
- Nomura Asset Management Co., Ltd.7.29%
- Wellington Management Co. LLP4.82%
- Eisai Co., Ltd.3.27%
- Amova Asset Management Co., Ltd.3.04%
- Nippon Life Insurance Co.2.23%
Share of the company, as of September 25, 2026
Leadership
- Haruo Naito — CEO, Representative Corporate Officer & Director, 78
- Takuya Oyama — Vice President, Chief Financial Officer & Chief IR Officer, 48
- Keisuke Naito — Representative Corporate Officer, EVP, COO & Chief Growth Officer, 37
- Terushige Iike — Executive VP, Rep. Corporate Officer & Chief Business Officer, 62
- Lynn D. Kramer FAAN, M.D. — VP & Chief Clinical Officer, 75
How much revenue does Eisai make?
Eisai reported 789.40 billion JPY in revenue for fiscal year 2025, up 6.4% from 741.75 billion JPY in fiscal year 2024.
What is Eisai's largest business segment?
Pharmaceutical Business - Americas, with 278.26 billion JPY or 35% of segment revenue in fiscal year 2025. Next: Pharmaceutical Business - Japan (27%) and Pharmaceutical Business - China (15%).
Where does Eisai make most of its revenue?
United States: 35% of revenue by region in fiscal year 2025, followed by Japan (29%).
What companies are similar to Eisai?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Otsuka Holdings Co., Ltd. (4578.T), Daiichi Sankyo Company, Limited (4568.T), Astellas Pharma Inc. (4503.T), Kyowa Kirin Co., Ltd. (4151.T).
How has Eisai's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 645.94 billion JPY; FY2022, 756.23 billion JPY; FY2023, 744.40 billion JPY; FY2024, 741.75 billion JPY; FY2025, 789.40 billion JPY.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Eisai Co., Ltd. (4523.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4523.T